Mentixa

Memantine Hydrochloride, the active ingredient in Mentixa, is a NMDA receptor antagonist presented as an oral tablet for oral use. It is indicated for the treatment of Alzheimer’s disease in adult patients, aiming to support cognition and daily functioning.

GNH USA supplies Mentixa as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, providing reliable sourcing and regulatory support for global healthcare providers. The company ensures product quality through stringent quality‑assurance processes and adheres to international standards for distribution.

Mentixa (memantine) is used in the management of Alzheimer’s disease, targeting glutamatergic neurotransmission to improve clinical outcomes.

- Alzheimer's disease (mild to moderate): helps maintain cognitive function and slows decline. - Alzheimer's disease (moderate to severe): may improve daily living activities and functional abilities. - Behavioral symptoms in Alzheimer’s disease: may reduce agitation and aggression.

Like all medications, memantine can cause adverse reactions, which are categorized by frequency and severity.

Common Side Effects: - Dizziness - Headache - Constipation - Nausea - Fatigue - Confusion

Serious or Rare Side Effects: - Severe skin reactions (e.g., Stevens‑Johnson syndrome) - Seizures - Hallucinations or psychosis - Cardiac arrhythmias - Significant liver injury

Before initiating therapy, clinicians should evaluate patient‑specific factors and monitor for potential complications.

- Renal impairment: adjust dose or monitor renal function. - Hepatic impairment: use with caution and monitor liver enzymes. - History of seizures: consider risk of increased seizure activity. - Concomitant use with other NMDA antagonists: avoid due to additive neurotoxicity. - Pregnancy and lactation: safety not established; weigh benefits against risks. - Store at ambient temperature: keep in the original pack, protect from moisture and direct sunlight.

Memantine may interact with other medicines, influencing efficacy or safety.

Major Interactions (Avoid): - Amantadine: increased risk of neurotoxicity. - Other NMDA antagonists: additive central nervous system effects. - Anticholinergic agents: may diminish therapeutic benefit.

Moderate Interactions (Monitor Closely): - CNS depressants (e.g., benzodiazepines): enhanced sedation. - Diuretics: potential for hypotension. - Antihypertensive drugs: monitor blood pressure for additive lowering effects.